Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.11 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A potential undervalued opportunity in healthcare
NOVO-NORDISK (NYSE:NVO) appears undervalued with strong profitability, solid growth, and a reasonable valuation, making it a potential candidate for value investors in the healthcare sector. 
Via Chartmill
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Via The Motley Fool
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles
GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns. 
Via Benzinga
Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunder
Via The Motley Fool
Topics Intellectual Property
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock at a Reasonable Valuation
NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks in the pharmaceutical sector. 
Via Chartmill
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Absurdly Cheap Growth Stocks to Load Up On Right Now
Via The Motley Fool
Topics World Trade
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes
An update on Sana Biotechnology. 
Via Benzinga
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing'
Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate. 
Via Benzinga
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
Via The Motley Fool
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady. 
Via Benzinga
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%. 
Via Stocktwits
Topics ETFs Government Stocks
Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europe
In addition to the submission to the EMA, Novo Nordisk aims to make the higher dose of Wegovy widely available throughout the European Union. 
Via Stocktwits
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes. 
Via Benzinga
WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation
WeightWatchers completes reorganization, adds new leadership and unveils a women's health initiative targeting menopause care. 
Via Benzinga
2 S&P 500 Dividend Stocks That Could Climb 17% or More, According to Wall Street
Via The Motley Fool
Topics Stocks
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock. 
Via Benzinga
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns. 
Via Benzinga
Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert
Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access. 
Via Benzinga
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Via The Motley Fool
2 Stocks to Buy on the Dip and Hold for 10 Years
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Is Hims & Hers Stock in Trouble?
Via The Motley Fool
Topics Supply Chain
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound. 
Via Benzinga
Amazon Wants More Power
Amazon's latest data center will reportedly require the same amount of electricity as 1 million homes. 
Via The Motley Fool
Topics Artificial Intelligence
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Via The Motley Fool
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.